In CLL, BTK-Inhibitor Resistance Remains a Confounding Problem
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).
Eli Lilly Abbvie Genentech Pharmacyclics Janssen Chronic Lymphocytic Leukemia Btk Inhibitor Noncovalent Btk Inhibitors
Source: ajmc.com